Serological response in cattle immunized with inactivated oil and Algel adjuvant vaccines against infectious bovine rhinotracheitis.
Infectious bovine rhinotracheitis (IBR) virus was grown in Madin Darby bovine kidney (MDBK) cell line using a roller culture system for its large-scale production. Optimum multiplicity of infection (MOI) of 1:750 was found to give consistent virus yield. To determine the appropriate payload, three batches of antigen with virus titres ranging from 10(8.37) to 10(6.37) TCID50 per ml were used to prepare experimental inactivated IBR oil adjuvant vaccine. Beta-propiolactone (BPL) was used as inactivant. The vaccine formulation using inactivated BHV-1 virus antigen with a pre-inactivation titer of 10(8.37) TCID50 per dose elicited better sero-conversion in cattle calves as evidenced from the mean log SN titre of 1.02. To choose the appropriate adjuvant, two batches of vaccine each containing aluminum hydroxide gel (Algel) and Montanide oil respectively were tested in calves. Two groups of 16 calves each were inoculated with Algel and oil adjuvant vaccine respectively twice at four weeks to test the immunogenicity. Adequate titres of vaccine induced anti BHV-1 antibodies could be demonstrated both by ELISA and MNT up to 180 days post vaccination in both the groups.
Kamaraj
G
G
Research and Development Centre, Indian Immunologicals Ltd. Gachibowli, Hyderabad, India.
Rana
S K
SK
Srinivasan
V A
VA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000627:therapeutic use*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000276:immunology; D002417:Cattle; D018929:Cell Culture Techniques; D002460:Cell Line; D007242:Herpesvirus 1, Bovine / Q000276:immunology; D022283:Herpesvirus Vaccines / Q000008:administration & dosage* / Q000138:chemical synthesis; D007241:Infectious Bovine Rhinotracheitis / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D008353:Mannitol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009500:Neutralization Tests; D009829:Oleic Acids / Q000627:therapeutic use*; D014611:Vaccination / Q000379:methods; D015164:Vaccines, Inactivated / Q000008:administration & dosage* / Q000138:chemical synthesis
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000956:Antigens, Viral; D022283:Herpesvirus Vaccines; D009829:Oleic Acids; D015164:Vaccines, Inactivated; C477385:montanide ISA 51; D008353:Mannitol; D000536:Aluminum Hydroxide